Dr. Arash Naghavi is an Associate Member with Tenure in the Department of Radiation Oncology at Moffitt Cancer Center, where he serves as the Section Chief for the Sarcoma Radiotherapy Service. After completing a Master of Science in Genetics, Medical Degree from the University of Texas Medical Branch, and Personalized Medicine Fellowship at Moffitt Cancer Center, he joined as faculty in 2017. Dr. Naghavi’s primary research interest is in the integration of genomics and radiomics to personalize the treatment of soft tissue sarcoma with the goal of expanding our knowledge in radiation sensitivity, immunogenicity, and identifying predictors and potential targets, to optimize patient outcomes. This has led to over 70 peer-reviewed manuscripts, including: sarcoma radiosensitivity or “Genomic Adjusted Radiation Dose (GARD)”, the relationships between pathologic response and outcome, and novel techniques (e.g. Hypofractionated Accelerated Radiation Dose-painting, or “HARD”) to improve outcomes for retroperitoneal sarcoma and unresected sarcoma. This has culminated in his ongoing phase II Habitat Escalated Adaptive Therapy (HEAT) trial (NCT05301283), utilizing MRI radiomic habitats to identify and target radioresistant intra-tumoral subpopulations with GARD estimated radiation dose escalation, to improve pathologic response and patient outcome.
Disclosures:
- Employment: none
- Compensation: none
- Ownership: none
- Leadership: none